In a pioneering medical step that strengthens the presence of precision medicine technologies in the Kingdom, I-ONE Molecular Imaging Center, affiliated with Wadi Jeddah, announced the launch of patient scanning using ¹⁸F-FES PET/CT and PET/MRI. This advanced molecular imaging technology supports the clinical evaluation of estrogen receptor-positive breast cancer cases.
The scan provides physicians with broader capabilities to assess functional estrogen receptors throughout the body, helping inform treatment decisions for suitable cases, particularly when biopsies are difficult to perform or when conventional imaging results are inconclusive.
The significance of this technology lies in its ability to add a functional dimension to medical imaging. Rather than only identifying disease locations, it also helps physicians better understand estrogen receptor activity, supporting hormonal therapy pathways and precision medicine approaches.
The launch of this service comes as part of Wadi Jeddah and its affiliated companies’ efforts to support healthcare innovation and adopt advanced molecular imaging solutions that enhance diagnostic quality and contribute to more precise, patient-centered healthcare.
